Abstract
Objectives The Coronavirus-19 (COVID-19) pandemic continues to impose formidable challenges on healthcare services. The dramatic curtailment of endoscopy and CT colonography capacity has adversely impacted on timely diagnosis of colorectal cancer (CRC). We describe a COVID-adapted pathway rapidly implemented to mitigate risk and maximise cancer diagnosis in patients referred with symptoms of suspected CRC during the pandemic.
Design The “COVID-adapted pathway” integrated multiple quantitative faecal immunochemical tests (qFIT), to enrich for significant colorectal disease. CT with oral contrast was used to detect gross pathology. Patients reporting ‘high-risk’ symptoms were triaged to qFIT+CT and the remainder underwent initial qFIT. Prospective data collection comprised referral category, symptoms, blood results, medical history, time to first test, qFIT and CT results.
Setting Tertiary colorectal unit which manages over 500 cancer patients annually.
Participants All patients referred as ‘urgent suspicious of cancer’ (USOC) were included. Overall 422 patients (median age 64 years, 220 females) were triaged using this pathway.
Main outcome measures Outcomes comprised cancer detection frequency.
Results Compared to the same time period (1st April – 31st May) in 2017-2019, we observed a 43% reduction in primary care referrals with suspected CRC (1071 referrals expected reducing to 609). Overall 422 patients (median age 64 years, 220 females) were triaged using this pathway. Most (84·6%) were referred as USOC. Of the 422 patients, 202 (47·9%) were triaged to CT and qFIT, 211 (50·0%) to qFIT only, eight (1·9%) to outpatient clinic, and one to colonoscopy. Fifteen (3·6%) declined investigation and seven (1·7%) were deemed unfit. We detected 13 cancers (3·1%); similar to the mean cancer detection rate from all referrals in 2017-2019 (3·3%).
Conclusions The response to the COVID-19 pandemic resulted in a marked reduction in referrals and cessation of key diagnostic services. Although this COVID-adapted pathway mitigated the adverse effects on diagnostic capacity, the overall reduction in expected diagnoses is very substantial. It is clear that the adverse impact of measures taken to constrain the pandemic will lead to many undetected cancers due to the decrease in referrals.
Trial registration Not applicable
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable. Study is reporting data as part of routine clinical care.
Clinical Protocols
https://doi.org/10.1002/bjs.11798
Funding Statement
This pathway was funded by NHS Lothian and the Scottish Government as part of routine clinical care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NHS Lothian
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified data is available from the corresponding author on request.
